ERT, a global leader in clinical endpoint data solutions, has announced the close of its merger with Bioclinica, a technological and scientific leader in clinical imaging. This combination creates the global leader in clinical trial endpoint technology and leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with an unrelenting focus on customer service.
Latham & Watkins LLP represented a consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company ERT in the transaction with a corporate deal team led by New York partner David Beller and London and Paris partner Thomas Forschbach.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.